Published in Cancer Weekly, September 24th, 2002
Research investigators at the University of Brescia in Italy have tested the effects of the antimetabolite 6-thioguanine (6-TG) on hematological cancers in vitro and in vivo, only to find that in addition to altering tumor metabolism, drugs of its type may also alter tumor-associated vascularization.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.